NEW Reducing Residual CVD Risk: Shifting the Cholesterol Conversation Beyond Statin Therapy
This activity will discuss the need to "shift the cholesterol conversation" beyond statin therapy by exploring the controversies surrounding the new ACC/AHA cholesterol guidelines, examining the role of CETP inhibition in lipid disorders, and discussing recent clinical trial data with CETP inhibitors currently in development. (Sep 2015)
Yehuda Handelsman, MD, FACP, FACE, FNLA (Activity Chair)
Eliot A Brinton, MD, FAHA, FNLA
Mikhail Kosiborod, MD